These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1497223)

  • 1. [Bone marrow transplantation in malignant diseases in childhood using reverse isolation technics: evaluation of results].
    Otheo de Tejada E; Maldonado Regalado MS; Muñoz Villa A; Pérez de Oteyza J; García Laraña J
    An Esp Pediatr; 1992 Jun; 36(6):433-6. PubMed ID: 1497223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Perreault C; Gyger M; Boileau J; Bonny Y; Cousineau S; Lacombe M; Lavallee R; Tawil E; D'Angelo G
    Can Med Assoc J; 1983 Nov; 129(9):969-74. PubMed ID: 6367917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow transplantation in childhood leukemia using reverse isolation techniques.
    Ogden AK; Steuber CP; Mahoney DH; Fernbach DJ
    Med Pediatr Oncol; 1990; 18(1):1-5. PubMed ID: 2403630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMV-viraemia during allogenic bone marrow transplantation in paediatric patients: association with survival and graft-versus-host disease.
    Matthes-Martin S; Aberle SW; Peters C; Holter W; Popow-Kraupp T; Pötschger U; Fritsch G; Ladenstein R; Rosenmayer A; Dieckmann K; Gadner H
    Bone Marrow Transplant; 1998 Apr; 21 Suppl 2():S53-6. PubMed ID: 9630327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
    Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA
    Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Infections in the neutropenic phase following bone marrow transplantation: comparison of laminar airflow isolation with conventional isolation].
    Gamillscheg A; Urban C; Slavc I; Lackner H; Hauer C
    Wien Klin Wochenschr; 1991; 103(3):82-7. PubMed ID: 2028617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Innsbruck results of bone marrow transplantation in treatment of hematologic neoplasms and solid tumors].
    Nachbaur D; Schwaighofer H; Thaler J; Weyrer W; Fink M; Nussbaumer W; Fritsch E; Niederwieser D
    Wien Klin Wochenschr; 1994; 106(7):201-7. PubMed ID: 8197754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic bone marrow transplantation for thalassemia in Taiwan: factors associated with graft failure.
    Lin KH; Lin KS
    Am J Pediatr Hematol Oncol; 1989; 11(4):417-23. PubMed ID: 2618976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
    Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
    Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experience using bone marrow transplantation in the treatment of hematologic neoplasms and solid tumors].
    Niederwieser D; Aulitzky W; Frommhold H; Schönitzer D; Url M; Allerberger F; Wiegele J; Gratwohl A; Braunsteiner H; Huber C
    Wien Klin Wochenschr; 1987 Jan; 99(2):49-53. PubMed ID: 3551339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program.
    Kimura F; Sato K; Kobayashi S; Ikeda T; Sao H; Okamoto S; Miyamura K; Mori S; Akiyama H; Hirokawa M; Ohto H; Ashida H; Motoyoshi K;
    Haematologica; 2008 Nov; 93(11):1686-93. PubMed ID: 18835834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
    Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
    Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic bone marrow transplantation in the treatment of hematologic diseases.
    Yee GC; McGuire TR
    Clin Pharm; 1985; 4(2):149-60. PubMed ID: 3886273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
    Byrne JL; Stainer C; Cull G; Haynes AP; Bessell EM; Hale G; Waldmann H; Russell NH
    Bone Marrow Transplant; 2000 Feb; 25(4):411-7. PubMed ID: 10723585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second allogeneic bone marrow transplants from unrelated donors for graft failure following initial unrelated donor bone marrow transplantation.
    Grandage VL; Cornish JM; Pamphilon DH; Potter MN; Steward CG; Oakhill A; Marks DI
    Bone Marrow Transplant; 1998 Apr; 21(7):687-90. PubMed ID: 9578308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimizing graft rejection in allogeneic T cell-depleted bone marrow transplantation.
    Rigden JP; Cornetta K; Srour EF; Hanna M; Broun ER; Hromas R; Baute J; Hilton J; Cox E; Rubin L; Gonin R; Tricot G
    Bone Marrow Transplant; 1996 Nov; 18(5):913-9. PubMed ID: 8932845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.